Glioblastoma Multiforme: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis

  • ID: 3797435
  • Drug Pipelines
  • 144 pages
  • Datamonitor Healthcare
1 of 3
The prognosis of patients with GBM remains poor as drug developers turn to immunotherapies to provide more effective options.

This report addresses the following questions:

- What is the current standard of care for patients with GBM in each treatment setting, and how effective are these options?
- What are the major challenges facing drug developers in GBM?
- How do the various PD-1 pathway inhibitors, gene therapies, and vaccines currently in development for GBM compare in terms of safety and efficacy?
- What patient segmentations are most relevant in the treatment of GBM?
Note: Product cover images may vary from those shown
2 of 3
TREATMENT: GLIOBLASTOMA MULTIFORME

- Executive Summary
- Primary Research Methodology
- Disease Definition and Diagnosis
- Patient Segmentation
- Country Treatment Trees
- Current Treatment Options
- Prescribing Trends
- Unmet Needs

EPIDEMIOLOGY: GLIOBLASTOMA MULTIFORME

- Executive Summary
- Disease Definition
- Global Variation
- Risk Factors
- Sources and Methodology
- Forecast
- Epidemiologist Insight
- Strengths and Limitations,
- Bibliography

MARKETED DRUGS: GLIOBLASTOMA MULTIFORME

- Executive Summary
- Product Overview
- Product profile: Avastin
- Product profile: Temodar

PIPELINE: GLIOBLASTOMA MULTIFORME

- Executive Summary
- Clinical Pipeline Overview
- Target Product Profile
- Clinical Trial Design
- Recently Discontinued Drugs
- Product profile (late stage): DCVax-L
- Product profile (late stage): ICT-1
- Product profile (late stage): Opdivo
- Product profile (late stage): Toca 511/FC
- Product profile (late stage): VB-111
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll